ITeos Therapeutics Analyst Ratings
ITeos Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/18/2023 | 251.06% | Wedbush | → $33 | Reiterates | Outperform → Outperform |
| 08/09/2023 | 368.09% | HC Wainwright & Co. | $54 → $44 | Maintains | Buy |
| 03/17/2023 | 474.47% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
| 03/16/2023 | 240.43% | JP Morgan | $34 → $32 | Maintains | Overweight |
| 03/16/2023 | 251.06% | Wedbush | $45 → $33 | Maintains | Outperform |
| 05/13/2022 | 527.66% | SVB Leerink | $60 → $59 | Maintains | Outperform |
| 12/13/2021 | 474.47% | HC Wainwright & Co. | $37 → $54 | Maintains | Buy |
| 11/12/2021 | 474.47% | SVB Leerink | $55 → $54 | Maintains | Outperform |
| 08/13/2021 | 485.11% | SVB Leerink | $56 → $55 | Maintains | Outperform |
| 05/19/2021 | 378.72% | SVB Leerink | $60 → $45 | Maintains | Outperform |
| 05/05/2021 | 293.62% | HC Wainwright & Co. | → $37 | Initiates Coverage On | → Buy |
| 04/06/2021 | 538.3% | SVB Leerink | $37 → $60 | Maintains | Outperform |
| 11/19/2020 | 293.62% | SVB Leerink | $36 → $37 | Maintains | Outperform |
| 10/08/2020 | 378.72% | Baird | → $45 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 325.53% | JP Morgan | → $40 | Initiates Coverage On | → Overweight |
| 08/18/2020 | 378.72% | Wedbush | → $45 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 282.98% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 431.91% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/18/2023 | 251.06% | 韋德布什 | →$33 | 重申 | 跑贏→跑贏大盤 |
| 08/09/2023 | 368.09% | HC Wainwright公司 | $54→$44 | 維護 | 買 |
| 03/17/2023 | 474.47% | HC Wainwright公司 | →$54 | 重申 | →購買 |
| 03/16/2023 | 240.43% | 摩根大通 | $34→$32 | 維護 | 超重 |
| 03/16/2023 | 251.06% | 韋德布什 | $45→$33 | 維護 | 跑贏大盤 |
| 2022年05月13日 | 527.66% | SVB Leerink | $60→$59 | 維護 | 跑贏大盤 |
| 2021年12月13日 | 474.47% | HC Wainwright公司 | $37→$54 | 維護 | 買 |
| 2021年11月12日 | 474.47% | SVB Leerink | $55→$54 | 維護 | 跑贏大盤 |
| 2021/08/13 | 485.11% | SVB Leerink | $56→$55 | 維護 | 跑贏大盤 |
| 2021/05/19 | 378.72% | SVB Leerink | $60→$45 | 維護 | 跑贏大盤 |
| 05/05/2021 | 293.62% | HC Wainwright公司 | →$37 | 開始承保 | →購買 |
| 04/06/2021 | 538.3% | SVB Leerink | $37→$60 | 維護 | 跑贏大盤 |
| 11/19/2020 | 293.62% | SVB Leerink | $36→$37 | 維護 | 跑贏大盤 |
| 10/08/2020 | 378.72% | 貝爾德 | →$45 | 開始承保 | →跑贏大盤 |
| 2020/08/18 | 325.53% | 摩根大通 | →$40 | 開始承保 | →超重 |
| 2020/08/18 | 378.72% | 韋德布什 | →$45 | 開始承保 | →跑贏大盤 |
| 2020/08/18 | 282.98% | SVB Leerink | →$36 | 開始承保 | →跑贏大盤 |
| 2020/08/18 | 431.91% | 派珀·桑德勒 | →$50 | 開始承保 | →超重 |
What is the target price for ITeos Therapeutics (ITOS)?
ITeos治療公司(ITOS)的目標價格是多少？
The latest price target for ITeos Therapeutics (NASDAQ: ITOS) was reported by Wedbush on October 18, 2023. The analyst firm set a price target for $33.00 expecting ITOS to rise to within 12 months (a possible 251.06% upside). 5 analyst firms have reported ratings in the last year.
韋德布什於2023年10月18日報道了iTeos治療公司(納斯達克：ITOS)的最新目標價。這家分析公司將目標價定為33美元，預計Itos將在12個月內上漲(可能上漲251.06%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for ITeos Therapeutics (ITOS)?
ITeos治療公司(ITOS)的最新分析師評級是多少？
The latest analyst rating for ITeos Therapeutics (NASDAQ: ITOS) was provided by Wedbush, and ITeos Therapeutics reiterated their outperform rating.
對iTeos治療公司(納斯達克代碼：ITOS)的最新分析師評級是由韋德布什公司提供的，iTeos治療公司重申了他們的表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for ITeos Therapeutics (ITOS)?
ITeos治療公司(ITOS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ITeos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ITeos Therapeutics was filed on October 18, 2023 so you should expect the next rating to be made available sometime around October 18, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與iTeos治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。ITeos治療公司的上一次評級是在2023年10月18日提交的，所以你應該預計下一次評級將在2024年10月18日左右的某個時候提供。
Is the Analyst Rating ITeos Therapeutics (ITOS) correct?
分析師對ITOS Treateutics(ITOS)的評級正確嗎？
While ratings are subjective and will change, the latest ITeos Therapeutics (ITOS) rating was a reiterated with a price target of $0.00 to $33.00. The current price ITeos Therapeutics (ITOS) is trading at is $9.40, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的iTeos治療公司(ITOS)評級被重申，目標價在0.00美元至33.00美元之間。目前iTeos治療公司(ITOS)的交易價格為9.40美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。